A recent study reported that RGS5 could impair the progression of NAFLD by preventing the hyperphosphorylation of transforming growth factor beta-activated kinase 1 (TAK1) and the activation of the downstream JNK/p38 signaling cascade [11]. Here, RGS5 is linked to metabolic dysfunction-associated steatotic liver disease.